Details for Patent: 12,569,453

Which drugs does patent 12,569,453 protect, and when does it expire?

Patent 12,569,453 protects VTAMA and is included in one NDA.

Summary for Patent: 12,569,453

Title:	Use of tapinarof for the treatment of atopic dermatitis
Abstract:	Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis or plaque psoriasis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3. Also described are clinical endpoints for treatment of subjects diagnosed with chronic mild to moderate plaque psoriasis for greater than or equal to 6 months, wherein about 3% to about 20% of body surface area was affected, and Physician Global Assessment (PGA) score was greater than or equal to 2.
Inventor(s):	John E. KRAUS, James Lee
Assignee:	Dermavant Sciences GmbH
Application Number:	US18/163,631
Patent Claim Types: see list of patent claims	Use; Composition;

United States Patent 12,569,453: Scope, Claim Construction, and Atopic Dermatitis Topical Tapinarof Landscape

US Drug Patent 12,569,453 claims a once-daily topical tapinarof regimen for mild to severe atopic dermatitis (AD) in subjects 2 years or older, with clinically defined itch and disease-improvement thresholds and a systemic exposure “below limit of detection” requirement. The claims are built around (i) a defined potency (about 1.0% tapinarof), (ii) dermatology endpoints (IGA and itch NRS), (iii) pharmacokinetics (systemic exposure below detection), and (iv) formulation embodiment (oil-in-water emulsion with specified excipient sets), plus (v) downstream metric-dependent dependent claims (EASI, BSA reduction, sleep/PRO improvements, durability after cessation).

What is the core independent claim and what does it legally lock down?

Claim 1 is the only independent method claim presented in the record supplied and is the scope anchor.

Claim 1 (method) elements (construction checklist)

1. Use/indication

   • Treating mild to severe atopic dermatitis
   • In a subject age 2 years or older

2. Therapeutic modality and dosing

   • Topical administration
   • Topical composition containing about 1.0% tapinarof
   • Once daily to affected areas

3. Efficacy thresholds

   • After administration, IGA improves by 2 grades
   • Achieves itch/pruritus NRS improvement ≥ 4 from baseline within 4 weeks

4. Systemic exposure limitation

   • Topical administration results in systemic exposure of tapinarof below the limit of detection

Practical legal effect of Claim 1

• The claim is tight on product strength (about 1.0% tapinarof).
• It is tight on regimen (once daily, topical to affected areas).
• It is tight on trial-defined outcomes (IGA 2-grade improvement and itch NRS ≥ 4 at ≤ 4 weeks).
• It is tight on pharmacokinetics (systemic exposure below detection), which can act as a non-infringement lever if a competitor formulation produces measurable systemic levels or fails the detection threshold.

How does claim scope expand with dependent claims?

The dependent claims narrow and specify formulation details and patient/endpoint constraints. They do not broaden beyond Claim 1’s funnel; they constrain.

Oil-in-water emulsion specification (Claims 2-4)

• Claim 2: topical composition is an oil-in-water emulsion.
• Claim 3: oil phase contains the following excipients:
  • Medium chain triglycerides
  • Propylene glycol
  • Non-ionic emulsifying wax
  • Diethylene glycol monoethyl ether
  • Polyoxyl stearyl ether-2
  • Polysorbate 80
  • Polyoxyl stearyl ether-20
  • Benzoic acid
  • Butylated hydroxytoluene
• Claim 4: water phase contains:
  • Sodium citrate
  • Edetate disodium
  • Citric acid monohydrate
  • Water

Scope implication: If a competitor uses a different emulsion architecture, different oil/water components, or different preservatives/antioxidant systems, it may avoid literal coverage of Claims 2-4, while still risking coverage under Claim 1 (unless the competitor also has the same systemic exposure and endpoints).

Age and body area narrowing (Claims 5-7)

• Claim 5: subject is 2 to 18 (not merely ≥2).
• Claim 6: application sites include body/arms/legs/back/chest/buttocks/neck/scalp and nail sites (fingernails, toenails) and combinations.
• Claim 7: AD severity by percent body surface area: ~3% to ~20% affected.

Scope implication: Literal infringement under dependent claims requires these constraints. Claim 6 also implies coverage may extend to scalp and nail regions if they are treated as “affected areas.”

Baseline severity threshold (Claim 8)

• Claim 8: baseline IGA score ≥ 3

Scope implication: A regimen for patients with lower baseline IGA may not fit the dependent claim, though Claim 1 already says “mild to severe” (so Claim 8 functions as a narrowing mechanism in dependent coverage).

Multi-endpoint dependent claims (Claims 9-19)

Claims 9-19 layer additional quantitative or qualitative improvement requirements after dosing.

Claim 9: further requires improvement of one or more symptoms measured by at least one assessment from:

• IGA, daily Itch/Pruritus NRS, EASI, total severity score, BSA, sleep quality, dry/rough skin, red/discolored skin, flaky skin, VAS for sleep, VAS for itch, and patient-reported outcomes.

Claim 10 (EASI):

• EASI improved ≥ 50% or ≥ 75%

Claim 11 (BSA):

• BSA affected decreased to < 20%

Claim 12 (sleep):

• sleep quality improved as measured by VAS for sleep

Claim 13 (PRO symptom domains):

• Patient reported outcomes improved (Subject Impressions of Severity type) with symptoms selected from:
  • itchy skin, red/discolored skin, bleeding, weeping/oozing, cracked skin, scaly/flaky skin, dry/rough skin, painful skin, burning skin, disturbed sleep

Claims 14 and 16 (time-course improvements):

• Claim 14: improvement after ~2 weeks, ~4 weeks, or ~8 weeks
• Claim 16: IGA improvement after ~2 weeks, ~4 weeks, or ~8 weeks

Claims 15 and 17 (durability after cessation):

• Claim 15: improvement continues for ~4 weeks after administration has ceased
• Claim 17: IGA improvement continues for ~4 weeks after administration has ceased

Claims 18-19 (additional assessment and PRO instruments):

• Claim 18: additional assessments include NRS, TSS, dry/rough, red/discolored, flaky skin, VAS sleep/itch, PRO, combinations
• Claim 19: PRO instruments specifically include:
  • Subject Impression of Severity and Change
  • Expanded Patient-Oriented Eczema Measure (POEM)
  • Daily Sign and Symptom Severity Diary

No systemic accumulation (Claim 20)

• Claim 20: repeat administration shows no accumulation of tapinarof in plasma.

Scope implication: This strengthens the systemic exposure defense beyond a single time point, tightening the PK profile that would be required to fall within the claim set.

What does this claim set imply for topical tapinarof competitors?

The claim is built to distinguish topical tapinarof from systemic JAK inhibitors and from topicals where systemic exposure can be measurable. Two infringement “gates” matter most:

1. Performance gate

   • IGA: +2 grades
   • Itch NRS: ≥ 4 improvement within 4 weeks

2. Exposure gate

   • Systemic exposure below limit of detection
   • No plasma accumulation with repeat dosing

A competitor trying to design around must generally do one of the following:

• Avoid about 1.0% tapinarof potency
• Avoid once daily or the claimed dosing to “affected areas”
• Fail the IGA and itch NRS thresholds at the defined time window
• Produce measurable systemic exposure (above limit of detection) or create plasma accumulation inconsistent with Claim 20
• For dependent formulation embodiments, avoid the oil and water phase excipient lists (Claims 2-4)

Because Claim 1 includes the systemic exposure limitation, formulation changes that increase systemic absorption could be more risky than changes that change excipient profiles alone, even if clinical efficacy is similar.

Where does the formulation matter most: Claim 1 or Claims 2-4?

• Claim 1 does not require an oil-in-water emulsion or the specific excipient set.
• Claims 2-4 do require specific formulation components (and thus are narrower).

Landscape implication: A competitor could be exposed to the broadest coverage (Claim 1) even with a different formulation architecture, so long as the potency, regimen, efficacy thresholds, and PK “below detection” conditions match. The excipient match primarily determines whether the competitor falls within the dependent embodiment coverage, not whether it is completely outside the patent.

How does the patent fit into the atopic dermatitis “topical small molecule” landscape?

Tapinarof is a topical aryl hydrocarbon receptor (AhR) modulator and sits in a well-defined competitive frame:

• Topical anti-inflammatory agents (steroids, calcineurin inhibitors)
• Topical JAK inhibitors (where marketed for AD)
• Topical PDE4 inhibitors (historically active in AD)
• Barrier repair strategies and emollients
• Topical immune modulators targeting molecular inflammatory pathways

In that frame, US 12,569,453 targets a specific, trial-like clinical phenotype and exposure profile:

• AD severity by IGA ≥ 3
• Baseline BSA roughly 3%-20% in dependent coverage
• Clinical endpoints with quantified itch reduction and IGA categorical shift
• PK designed to show undetectable systemic exposure and no accumulation

This structure typically functions to:

• Position the drug for pediatric and mixed-severity populations (2 to 18 explicitly in Claim 5)
• Reinforce differentiation from systemic therapies by requiring systemic exposure below detection

What is the scope of “success” under the claims (and what metrics could trap infringement)?

Claim 1 sets the “must-hit” metrics

• IGA improves by 2 grades
• Itch NRS improvement ≥ 4 from baseline within 4 weeks
• Systemic exposure below limit of detection

Dependent claims broaden “success” measurement to additional axes

• EASI improvement with thresholds (50% or 75%)
• BSA reduction to <20%
• Sleep via VAS for sleep improvements
• Symptom domain improvements captured by PRO instruments and patient diaries

For landscape risk, the key is that the claims use a menu in multiple dependent claims. A competitor strategy that “hits” the primary endpoints while failing only one PRO domain could still satisfy a dependent claim if another instrument/endpoint in the list improves.

What is the likely freedom-to-operate posture for adjacent topical candidates?

Based on claim structure alone, topical candidates with:

• similar potency (about 1.0% tapinarof),
• similar dosing (once daily),
• similar clinical endpoint magnitudes, and
• a PK profile with systemic exposure below detection

would be at elevated infringement risk on Claim 1.

Candidates that differ mainly by:

• emollient/excipient design that does not change the drug’s systemic absorption behavior, or
• dosing frequency, would still need to show failure against the IGA/itch thresholds and/or the PK below detection requirement to create meaningful design space.

Candidates with measurable systemic exposure would tend to avoid the Claim 1 exposure gate, even if efficacy is similar, assuming the measured systemic exposure is not “below the limit of detection.”

How strong is the patent as a barrier: what the claim set suggests about enforcement leverage

The patent has multiple enforcement levers:

• Clear clinical endpoints with timing (4 weeks for itch; IGA improvement by 2 grades)
• PK thresholds that can be measured and compared (below detection and no accumulation)
• Formulation-dependent dependent claims that can target specific generic or follow-on formulations

This matters because competitors often attempt to steer toward “design arounds” by altering excipients, but the claims include systemic exposure and clinical improvements tied to specific magnitude thresholds, increasing the burden on design changes.

Key Takeaways

• US 12,569,453 Claim 1 is a method claim for once-daily topical tapinarof at about 1.0% to treat mild to severe AD in patients ≥2 years, requiring IGA +2 grades and itch NRS improvement ≥4 within 4 weeks, with systemic tapinarof exposure below the limit of detection.
• Dependent claims narrow coverage by formulation (oil-in-water emulsion with enumerated excipients), age (2-18), BSA (3%-20% affected), baseline IGA ≥3, and by additional validated outcome measures including EASI, sleep VAS, and PRO instruments.
• Systemic exposure below detection and “no plasma accumulation” (Claim 20) are the most meaningful design-around handles, because they directly constrain infringement beyond clinical outcomes.
• A competitor that matches efficacy but has detectable systemic exposure could avoid the Claim 1 exposure gate; a competitor that matches PK but fails IGA/itch thresholds would also reduce risk.

FAQs

1. Does US 12,569,453 require a specific emulsion formulation to infringe?
   No. Emulsion and excipient requirements appear in dependent claims (Claims 2-4). Claim 1 only requires about 1.0% tapinarof, topical once-daily dosing, defined clinical improvements, and systemic exposure below detection.

2. What clinical targets are mandatory in the independent claim?
   IGA improves by 2 grades and itch/pruritus NRS improves by ≥4 from baseline within 4 weeks.

3. What patient population does the patent cover?
   Claim 1 covers subjects aged 2 years or older. Claim 5 narrows dependent coverage to 2 to 18.

4. Is systemic exposure a one-time threshold or a repeat-dosing constraint?
   Claim 1 requires systemic exposure after administration is below the limit of detection. Claim 20 adds that repeat dosing shows no accumulation of tapinarof in plasma.

5. Do dependent claims broaden which outcomes can be used to prove success?
   Yes. Claims 9, 18, and 19 use a set of assessments and PRO instruments; satisfying any listed measure can support dependent claim coverage where the related criteria are met.

References

[1] United States Patent No. 12,569,453 (claim text provided by user).

Drugs Protected by US Patent 12,569,453

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes	12,569,453					TOPICAL TREATMENT OF ATOPIC DERMATITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER